FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:640-642 February 5, 2009 Number 6 Next

Prevalence of Mitochondrial 1555AG Mutation in European Children

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Supplementary Material Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Aminoglycoside antibiotics are used worldwide to treat gram-negative sepsis. Since these drugs are ototoxic and nephrotoxic, drug levels are closely monitored. However, their effect on patients with the mitochondrial DNA mutation m.1555AG is dramatic. Carriers of this mutation have permanent, profound hearing loss after receiving aminoglycosides, even when drug levels are within the therapeutic range.^1,2 A review of previous studies indicates that after aminoglycoside exposure, penetrance of deafness in this population is close to 100%.³

Estimates of the prevalence of the m.1555AG mutation have been hampered because of the small numbers of patients in such . . . [Full Text of this Article]

This article has been cited by other articles:

• Rahman, S, Hanna, M G (2009). Diagnosis and therapy in neuromuscular disorders: diagnosis and new treatments in mitochondrial diseases. J. Neurol. Neurosurg. Psychiatry 80: 943-953 [Abstract] [Full Text]  
• Vandebona, H., Mitchell, P., Manwaring, N., Griffiths, K., Gopinath, B., Wang, J. J., Sue, C. M. (2009). Prevalence of Mitochondrial 1555A->G Mutation in Adults of European Descent. NEJM 360: 642-644 [Full Text]